Related Experiment Video

Updated: Jan 30, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.4K

SGLT2 inhibitor therapy and clinical outcomes in HIV-related cardiomyopathy

Hesham Sheashaa1, Ramzi Ibrahim1, Hoang Nhat Pham2,3

  • 1Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ, USA.

American Heart Journal Plus : Cardiology Research and Practice
|January 29, 2026
PubMed

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) significantly reduce mortality and hospitalizations in patients with HIV cardiomyopathy (HIV-CM). This finding offers new hope for managing this complex cardiovascular condition.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • HIV cardiomyopathy (HIV-CM) presents significant health risks.
  • Sodium-glucose cotransporter 2 inhibitors (SGLT2i) show promise for heart failure (HF).
  • The efficacy of SGLT2i in HIV-CM remains largely unexplored.

Purpose of the Study:

  • To investigate the impact of SGLT2i on outcomes in patients with HIV-CM.
  • To compare mortality and hospitalization rates between HIV-CM patients with and without SGLT2i therapy.

Main Methods:

  • A cohort of 2606 patients with HIV-CM was analyzed using the TriNetX Network.
  • Patients receiving SGLT2i were propensity score matched with a control group not on SGLT2i.
  • Primary endpoint was all-cause mortality; secondary endpoints included hospitalizations and major adverse cardiovascular events.

Main Results:

  • SGLT2i use was linked to a significant reduction in all-cause mortality (HR 0.475).
  • SGLT2i therapy also significantly decreased all-cause hospitalizations (HR 0.725).
  • No significant differences were found for acute heart failure, myocardial infarction, stroke, or cardiac arrest.

Conclusions:

  • SGLT2i therapy demonstrates a significant survival benefit for patients with HIV-CM.
  • SGLT2i use is associated with reduced hospitalization rates in this patient population.
  • Further research may elucidate SGLT2i's role in specific cardiovascular event prevention within HIV-CM.
Abstract

Keywords:
CardiomyopathyCardiovascularHIVSGLT2-inhibitor

More Related Videos

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

32.2K
Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors08:33

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Published on: January 19, 2015

9.3K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
557
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
483
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
526
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
439
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
599